- An in vitro study found napabucasin to be effective in inhibiting diffuse large beta cell lymphoma (DLBCL) in cell lines.
- In addition, the effects of napabucasin were synergistic with the use of doxorubicin, a standard therapy for DLBCL.
Why this matters
- Although the signal transducer and activator of transcription 3 (STAT3) pathway plays a key role in the development of many cancers, there have not been any drugs approved for clinical use yet.
- Napabucasin is a novel, small-molecule inhibitor of STAT3.
- Researchers tested the effects of napabucasin on various DLBCL cell lines.
- Funding: Chinese government.
- 34% of patients with DLBCL expressed STAT3 in tumor tissues.
- Napabucasin showed potent cytotoxicity in a dose-dependent manner.
- Napabucasin also induced intrinsic and extrinsic cell apoptosis; downregulated the expression of STAT3 target genes, including the antiapoptotic protein Mcl-1; and regulated the mitogen-activated protein kinase pathway.
- In cells treated with napabucasin and doxorubicin alone and in combination, napabucasin alone significantly suppressed tumor growth compared with the control (P<.01 achieving tumor growth inhibition of>
- The combination treatment was significantly more effective than doxorubicin monotherapy (TGI, 98.2% vs 63.2%; P<.05>
- In vitro findings may not reflect clinical efficacy.